West Nile Virus (WNV)

Categories: Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for West Nile Virus

MalaCards integrated aliases for West Nile Virus:

Name: West Nile Virus 56 74 42
West Nile Virus, Susceptibility to 56 29 13 6 39
Encephalitis, West Nile Fever 71
West Nile Viral Infection 71
Wnv, Susceptibility to 56
West-Nile Encephalitis 58
West Nile Fever 71
West-Nile Fever 58
Wnv 56


Orphanet epidemiological data:

west-nile encephalitis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (United States),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;


Orphanet: 58  
Rare neurological diseases
Rare infectious diseases

External Ids:

OMIM 56 610379
ICD10 via Orphanet 33 A92.3
UMLS via Orphanet 72 C0043124 C0751583
Orphanet 58 ORPHA83476
UMLS 71 C0043124 C0751583 C1096184

Summaries for West Nile Virus

MedlinePlus : 42 West Nile virus (WNV) is an infectious disease that first appeared in the United States in 1999. Infected mosquitoes spread the virus that causes it. People who get WNV usually have no symptoms or mild symptoms. The symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. They can last a few days to several weeks, and usually go away on their own. If West Nile virus enters the brain, however, it can be life-threatening. It may cause inflammation of the brain, called encephalitis, or inflammation of the tissue that surrounds the brain and spinal cord, called meningitis. A physical exam, medical history, and laboratory tests can diagnose it. Older people and those with weakened immune systems are most at risk. There are no specific vaccines or treatments for human WNV disease. The best way to avoid WNV is to prevent mosquito bites: Use insect repellent Get rid of mosquito breeding sites by emptying standing water from flower pots, buckets or barrels Stay indoors between dusk and dawn, when mosquitoes are most active Use screens on windows to keep mosquitoes out

MalaCards based summary : West Nile Virus, also known as west nile virus, susceptibility to, is related to west nile virus infection and west nile fever, and has symptoms including seizures, fever and pruritus. An important gene associated with West Nile Virus is CCR5 (C-C Motif Chemokine Receptor 5), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Maraviroc and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotype is Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection.

OMIM : 56 WNV is an enveloped, neurotropic, single-stranded sense RNA flavivirus that is naturally maintained in a zoonotic cycle between avian hosts and mosquito vectors. The virus was first isolated from a Ugandan woman in 1937 and subsequently emerged in Europe and, in 1999, in New York, with eventual spread throughout North America. WNV causes a spectrum of disease ranging from acute fever to lethal encephalitis. Susceptibility to WNV is increased in the elderly and in immunocompromised individuals (summary by Diamond and Klein (2006) and Glass et al. (2005)). (610379)

Wikipedia : 74 West Nile virus (WNV) is a single-stranded RNA virus that causes West Nile fever. It is a member of the... more...

Related Diseases for West Nile Virus

Diseases related to West Nile Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 west nile virus infection 35.2 IRF3 CCR5
2 west nile fever 33.9 CLEC4M CD209 CCR5
3 west nile encephalitis 33.4 CLEC4M CCR5
4 yellow fever 31.2 SPCS1 RSAD2 CCR5
5 chikungunya 31.0 RSAD2 DDX58 CD209
6 rift valley fever 30.5 IFITM3 IFITM2 IFITM1 CD209
7 japanese encephalitis 30.4 SPCS1 RSAD2 IFNA1 CLEC4M CD209
8 avian influenza 30.2 IFNA1 DDX58 CCR5
9 encephalitis 30.0 SPCS1 RSAD2 IRF3 IFNA1 DDX58 CLEC4M
10 tick-borne encephalitis 30.0 RSAD2 IFNA1 DDX58 CD209 CCR5
11 newcastle disease 30.0 IRF3 IFNA1 DDX58
12 rabies 29.9 IRF3 IFNA1 DDX58
13 human immunodeficiency virus type 1 29.7 IRF3 CLEC4M CD209 CCR5AS CCR5
14 dengue shock syndrome 29.6 IFNA1 CLEC4M CD209
15 dengue virus 29.5 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 EXOC1
16 measles 29.4 IRF3 IFNA1 IFIH1 DDX58 CD209
17 viral infectious disease 29.3 IRF3 IFNA1 IFIH1 DDX58 CLEC4M CD209
18 stomatitis 29.2 RSAD2 IFNA1 IFITM3 IFITM2 DDX58
19 severe acute respiratory syndrome 29.2 IRF3 IFNA1 IFIH1 DDX58 CLEC4M CD209
20 mouth disease 29.0 ITGAV IRF3 IFNA1 IFIH1 DDX58
21 hepatitis c 28.9 RSAD2 IRF3 IFNA1 DDX58 CLEC4M CCR5
22 hepatitis c virus 28.8 SPCS1 RSAD2 IRF3 IFITM3 IFITM1 DDX58
23 thrombocytopenia 28.6 ITGB3 IFNA1 IFIH1 CFH CD209
24 herpes simplex 28.5 ITGAV IRF3 IFNA1 IFIH1 DDX58 CD209
25 influenza 27.6 RSAD2 IRF3 IFNA1 IFITM3 IFITM2 IFITM1
26 west nile virus encephalitis 13.0
27 kunjin encephalitis 11.6
28 acute flaccid myelitis 11.6
29 meningoencephalitis 11.0
30 st. louis encephalitis 10.9
31 viral encephalitis 10.9
32 poliomyelitis 10.8
33 exanthem 10.8
34 triiodothyronine receptor auxiliary protein 10.7
35 meningitis 10.7
36 tremor 10.7
37 ataxia and polyneuropathy, adult-onset 10.7
38 chorioretinitis 10.7
39 aseptic meningitis 10.7
40 myocarditis 10.7
41 meningitis and encephalitis 10.6
42 myelitis 10.6
43 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.6
44 eastern equine encephalitis 10.6
45 pica disease 10.6
46 murray valley encephalitis 10.5
47 guillain-barre syndrome 10.5
48 vasculitis 10.5
49 myoclonus 10.5
50 neuritis 10.5

Graphical network of the top 20 diseases related to West Nile Virus:

Diseases related to West Nile Virus

Symptoms & Phenotypes for West Nile Virus

Clinical features from OMIM:


UMLS symptoms related to West Nile Virus:

seizures, fever, pruritus, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to West Nile Virus according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.32 IFIH1

Drugs & Therapeutics for West Nile Virus

Drugs for West Nile Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
2 Vaccines Phase 4
3 Antiviral Agents Phase 4
4 Anti-Infective Agents Phase 4
5 Anti-HIV Agents Phase 4
6 Anti-Retroviral Agents Phase 4
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
Nitazoxanide Approved, Investigational, Vet_approved Phase 2, Phase 3 55981-09-4 41684
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
10 Antiprotozoal Agents Phase 2, Phase 3
11 Antiparasitic Agents Phase 2, Phase 3
12 Antimalarials Phase 2, Phase 3
13 Antirheumatic Agents Phase 2, Phase 3
Ribavirin Approved Phase 2 36791-04-5 37542
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
17 Molgramostim Investigational Phase 2 99283-10-0
18 Antimetabolites Phase 2
19 Pharmaceutical Solutions Phase 2
20 Rho(D) Immune Globulin Phase 2
21 gamma-Globulins Phase 2
22 Immunoglobulins, Intravenous Phase 2
23 Immunoglobulin G Phase 2
24 Immunoglobulins Phase 2
25 Antibodies Phase 2
26 Antibodies, Monoclonal Phase 2
27 Immunologic Factors Phase 2
Aluminum sulfate Approved Phase 1 10043-01-3
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens Terminated NCT01049204 Phase 4 Maraviroc;placebo
2 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial Recruiting NCT04391127 Phase 3 Hydroxychloroquine;Ivermectin;Placebo
3 Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial Not yet recruiting NCT04387760 Phase 2, Phase 3 Hydroxychloroquine;Favipiravir
4 Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04360356 Phase 2, Phase 3
5 Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial Unknown status NCT00216268 Phase 2 Ribavirin
6 Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults. Completed NCT00746798 Phase 2
7 Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults Completed NCT00442169 Phase 2
8 A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV) Completed NCT00069316 Phase 2 Omr-IgG-am
9 A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis Completed NCT00068055 Phase 1, Phase 2 Omr-lgG-am;Polygam® S/D;Placebo
10 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
11 Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) Completed NCT00711035 Phase 1, Phase 2
12 Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus Terminated NCT00927953 Phase 2
13 Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant Terminated NCT01174082 Phase 2 GM-CSF
14 Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis Completed NCT00537147 Phase 1
15 Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis Completed NCT00094718 Phase 1
16 A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects Completed NCT00300417 Phase 1 VRC-WNVDNA020-00-VP
17 A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers Completed NCT00106769 Phase 1 VRC-WNVDNA017-00-VP
18 Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´Δ30 Chimeric Virus Vaccine (WN/DEN4Δ30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age Completed NCT02186626 Phase 1
19 A Double Blind, Randomized, Placebo-Controlled, Phase I Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults Completed NCT02337868 Phase 1
20 Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults Completed NCT00707642 Phase 1
21 Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration Completed NCT00387283 Phase 1 AVI-4020 Injection
22 A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults Completed NCT00515385 Phase 1 MGAWN1;MGAWN1
23 Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration Completed NCT00381433 Phase 1 AVI-4065 Injection
24 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
25 An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting With Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease Terminated NCT00091845 Phase 1 AVI-4020 Injection
26 Assessment of the Impact of Notification of Blood Donors Testing Positive for Microbiology Markers: What is the Psychological Impact of Notification and Does the Method of Notification Influence the Outcome? Unknown status NCT01050881
27 Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease Completed NCT00069303
28 Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease Completed NCT00138463
29 Surveillance of Summer Febrile Syndromes of Viral Origin in South of France Completed NCT00842166
30 VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases Completed NCT00068926
31 Retrovirus Epidemiology Donor Study-II (REDS-II) Completed NCT00097006
32 Pilot Study to Detect DENGUE Virus in Sperm. Completed NCT03612609
33 Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at "Ultra-High" Risk for Invasive Fungal Infections Completed NCT00177801
34 Clinical Evaluation of the FilmArray® Global Fever (GF) Panel Recruiting NCT02968355
35 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r Recruiting NCT01099852
36 Autologous Ovarian Tissue Transplantation Recruiting NCT03496636
37 The Collection and Storage of Umbilical Cord Blood for Transplantation Recruiting NCT01728545
38 The Threat of Infectious Encephalitis in Southeast Asia: SouthEast Asia Encephalitis Project Active, not recruiting NCT04089436
39 Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols Enrolling by invitation NCT00068003
40 Prospective Investigation of Oxidative Stress in West Nile Virus Infection Not yet recruiting NCT04371003
41 Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus No longer available NCT01206504

Search NIH Clinical Center for West Nile Virus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Genetic Tests for West Nile Virus

Genetic tests related to West Nile Virus:

# Genetic test Affiliating Genes
1 West Nile Virus, Susceptibility to 29 CCR5

Anatomical Context for West Nile Virus

MalaCards organs/tissues related to West Nile Virus:

Testes, Brain, T Cells, Spinal Cord, Skin, B Cells, Kidney

Publications for West Nile Virus

Articles related to West Nile Virus:

(show top 50) (show all 6349)
# Title Authors PMID Year
CCR5 deficiency increases risk of symptomatic West Nile virus infection. 6 56 61
16418398 2006
A complement-microglial axis drives synapse loss during virus-induced memory impairment. 61 56
27337340 2016
Host genetic risk factors for West Nile virus infection and disease progression. 61 56
21935451 2011
Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. 61 56
21131425 2011
Tregs control the development of symptomatic West Nile virus infection in humans and mice. 61 56
19855131 2009
Key role of T cell defects in age-related vulnerability to West Nile virus. 61 56
19901080 2009
Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. 56 61
19247438 2009
Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. 61 56
19200759 2009
Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. 56 61
17909632 2007
A genetic basis for human susceptibility to West Nile virus. 61 56
16750369 2006
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. 61 56
16651386 2006
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. 56 61
16230476 2005
Clinical Quandaries Posed by Concurrent Human Immunodeficiency Virus (HIV) and West Nile Virus (WNV) infections: Case Report. 42 61
32150640 2020
West Nile virus capsid protein inhibits autophagy by AMP-activated protein kinase degradation in neurological disease development. 61 42
31971978 2020
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 6
19017985 2008
The geographic spread of the CCR5 Delta32 HIV-resistance allele. 6
16216086 2005
The case for selection at CCR5-Delta32. 6
16248677 2005
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. 6
15863470 2005
Reappraisal of the historical selective pressures for the CCR5-Delta32 mutation. 6
15744032 2005
A mutated CCR5 gene may have favorable prognostic implications in MS. 6
12874407 2003
Absence of the HIV-1 protective Delta ccr5 allele in most ethnic populations of India. 6
11781692 2001
The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV. 6
11517319 2001
Chemokine receptor polymorphism in transplantation immunology: no longer just important in AIDS. 6
11403804 2001
CC chemokine receptor 5 and renal-transplant survival. 6
11403814 2001
Delta 32 deletion of CCR5 gene and association with asthma or atopy. 6
11081537 2000
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. 6
10803840 2000
Prevalence of CCR5delta32 in allergic diseases. 6
10615909 2000
Association of CCR5 delta32 with reduced risk of asthma. 6
10520641 1999
Distribution of the CCR5 gene 32-bp deletion in Europe. 6
9768627 1998
Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. 6
9585595 1998
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 6
9600249 1998
The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. 6
9466996 1998
First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene. 6
9511755 1998
The extent of genetic variation in the CCR5 gene. 6
9207783 1997
Global distribution of the CCR5 gene 32-basepair deletion. 6
9140404 1997
HIV-1 infection in an individual homozygous for the CCR5 deletion allele. 6
9055842 1997
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 6
9132277 1997
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 6
8756719 1996
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 6
8751444 1996
Fatal case of West Nile encephalitis associated with acute anteroseptal ST elevation myocardial infarction (STEMI): a case report. 42
32334492 2020
Evidence of West Nile virus infection in migratory and resident wild birds in west coast of peninsular Malaysia. 61
32405525 2020
Personalized adapted locomotor training for an individual with sequelae of West Nile virus infection: a mixed-method case report. 61
30136877 2020
Nontransient third-degree heart block and persistent respiratory findings as sequelae of acute occupational exposure to pyrethroids insecticide. 61
32297674 2020
Infectious and Autoimmune Causes of Encephalitis in Children. 61
32358069 2020
Feeding Habits of Vector Mosquitoes in Harris County, TX, 2018. 61
32574364 2020
West Nile Virus-associated Hospitalizations, California, USA, 2004-2017. 61
32525967 2020
A Molecular Determinant of West Nile Virus Secretion and Morphology as a Target for Viral Attenuation. 61
32269117 2020
West Nile virus lineage 2 in humans and mosquitoes in Bulgaria, 2018-2019. 61
32305885 2020
An unusual case of unilateral chorioretinitis and blind spot enlargement associated with asymptomatic West Nile virus infection. 61
32373759 2020
Landscape and demographic determinants of Culex infection with West Nile virus during the 2012 epidemic in Dallas County, TX. 61
32370939 2020

Variations for West Nile Virus

ClinVar genetic disease variations for West Nile Virus:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CCR5 NM_000579.3(CCR5):c.554_585del (p.Ser185fs)deletion Benign 8184 rs333 3:46414944-46414975 3:46373453-46373484

Expression for West Nile Virus

Search GEO for disease gene expression data for West Nile Virus.

Pathways for West Nile Virus

Pathways related to West Nile Virus according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 12.52 ITGB3 IRF3 IFNA1 IFIH1 DDX58
Show member pathways
Show member pathways
12.33 IRF3 IFNA1 IFIH1 DDX58
Show member pathways
12.29 IRF3 IFNA1 IFIH1 DDX58
8 12.28 RSAD2 IRF3 IFNA1 IFIH1 DDX58
Show member pathways
10 11.89 ITGB3 ITGAV CLEC4M CD209
11 11.78 ITGB3 ITGAV CD209
Show member pathways
13 10.87 ITGB3 ITGAV
14 10.62 ITGB3 ITGAV
15 10.54 ITGB3 ITGAV

GO Terms for West Nile Virus

Cellular components related to West Nile Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 RTN3 LY6E ITGB3 ITGAV IFITM3 IFITM2
2 ruffle membrane GO:0032587 9.5 ITGB3 ITGAV DDX58
3 lamellipodium membrane GO:0031258 9.43 ITGB3 ITGAV
4 filopodium membrane GO:0031527 9.37 ITGB3 ITGAV
5 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 9.26 ITGB3 ITGAV
6 alphav-beta3 integrin-HMGB1 complex GO:0035868 9.16 ITGB3 ITGAV
7 alphav-beta3 integrin-PKCalpha complex GO:0035866 8.96 ITGB3 ITGAV
8 integrin alphav-beta3 complex GO:0034683 8.62 ITGB3 ITGAV

Biological processes related to West Nile Virus according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 RSAD2 IRF3 IFITM3 IFITM2 IFITM1 IFIH1
2 response to virus GO:0009615 9.85 RSAD2 IFITM3 IFITM2 IFITM1 IFIH1 DDX58
3 innate immune response GO:0045087 9.85 RSAD2 IRF3 IFITM3 IFITM2 IFITM1 IFIH1
4 viral entry into host cell GO:0046718 9.83 ITGB3 ITGAV CLEC4M CD209
5 response to exogenous dsRNA GO:0043330 9.77 IRF3 IFNA1 DDX58
6 negative regulation of type I interferon production GO:0032480 9.76 IRF3 IFIH1 DDX58
7 positive regulation of interferon-beta production GO:0032728 9.75 IRF3 IFIH1 DDX58
8 type I interferon signaling pathway GO:0060337 9.73 RSAD2 IRF3 IFNA1 IFITM3 IFITM2 IFITM1
9 response to interferon-gamma GO:0034341 9.71 IFITM3 IFITM2 IFITM1
10 negative regulation of viral genome replication GO:0045071 9.71 RSAD2 IFITM3 IFITM2 IFITM1
11 cellular response to exogenous dsRNA GO:0071360 9.69 IRF3 IFIH1 DDX58
12 apoptotic cell clearance GO:0043277 9.68 ITGB3 ITGAV
13 cell adhesion mediated by integrin GO:0033627 9.67 ITGB3 ITGAV
14 cell-substrate adhesion GO:0031589 9.67 ITGB3 ITGAV
15 viral genome replication GO:0019079 9.67 CLEC4M CD209
16 negative regulation of viral entry into host cell GO:0046597 9.67 IFITM3 IFITM2 IFITM1
17 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.66 ITGB3 ITGAV
18 positive regulation of interferon-alpha secretion GO:1902741 9.66 IFIH1 DDX58
19 negative regulation of lipid storage GO:0010888 9.65 ITGB3 ITGAV
20 positive regulation of response to cytokine stimulus GO:0060760 9.65 IFIH1 DDX58
21 modulation by virus of host morphology or physiology GO:0019048 9.65 CLEC4M CD209
22 positive regulation of interferon-alpha production GO:0032727 9.65 IRF3 IFIH1 DDX58
23 apolipoprotein A-I-mediated signaling pathway GO:0038027 9.64 ITGB3 ITGAV
24 cell-cell recognition GO:0009988 9.64 CLEC4M CD209
25 detection of virus GO:0009597 9.63 IFIH1 DDX58
26 positive regulation of interferon-beta secretion GO:0035549 9.63 IFIH1 DDX58
27 response to interferon-beta GO:0035456 9.63 IFITM3 IFITM2 IFITM1
28 virion attachment to host cell GO:0019062 9.62 CLEC4M CD209
29 negative regulation of lipid transport GO:0032369 9.62 ITGB3 ITGAV
30 peptide antigen transport GO:0046968 9.61 CLEC4M CD209
31 negative regulation of low-density lipoprotein particle receptor biosynthetic process GO:0045715 9.61 ITGB3 ITGAV
32 response to interferon-alpha GO:0035455 9.61 IFITM3 IFITM2 IFITM1
33 defense response to virus GO:0051607 9.61 RSAD2 IRF3 IFNA1 IFITM3 IFITM2 IFITM1
34 MDA-5 signaling pathway GO:0039530 9.6 IRF3 IFIH1
35 negative regulation of lipoprotein metabolic process GO:0050748 9.57 ITGB3 ITGAV
36 cytoplasmic pattern recognition receptor signaling pathway in response to virus GO:0039528 9.56 IFIH1 DDX58
37 regulation of type III interferon production GO:0034344 9.55 IFIH1 DDX58
38 viral process GO:0016032 9.4 RTN3 RSAD2 ITGB3 ITGAV IRF3 IFIH1

Molecular functions related to West Nile Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mannose binding GO:0005537 9.4 CLEC4M CD209
2 virion binding GO:0046790 9.37 CLEC4M CD209
3 insulin-like growth factor I binding GO:0031994 9.32 ITGB3 ITGAV
4 neuregulin binding GO:0038132 9.26 ITGB3 ITGAV
5 C-X3-C chemokine binding GO:0019960 9.16 ITGB3 ITGAV
6 coreceptor activity GO:0015026 9.13 ITGB3 ITGAV CCR5
7 virus receptor activity GO:0001618 9.02 ITGB3 ITGAV CLEC4M CD209 CCR5

Sources for West Nile Virus

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....